• Grace Therapeutics posted a fiscal 2026 net loss of $7.8 million, narrowing from $9.6 million a year earlier.
• Loss per share improved to $0.47 from $0.79 in fiscal 2025.
• R&D expense fell to $2.4 million from $9.5 million, reflecting the close-out of the Phase 3 STRIVE-ON safety trial.
• G&A expense rose to $8.7 million from $7.2 million, driven by non-recurring legal and due diligence costs and pre-commercial planning.
• Cash totaled $17 million at March 31, 2026; an FDA Type A meeting is scheduled after an April CRL tied to CMC and non-clinical items.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grace Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-025667), on June 18, 2026, and is solely responsible for the information contained therein.